Q-omics provides the consensus-scored CYSRT1 profile across patient tissues and cancer cell-line models. CYSRT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYSRT1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CYSRT1 RNA expression shows 17,267 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where CYSRT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYSRT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYSRT1 survival associations across molecular data types. CYSRT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYSRT1 RNA expression–survival associations across cancer types. High CYSRT1 expression shows unfavorable associations in KIRC, ACC, UCS, COAD and PRAD, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYSRT1 RNA expression.
This table summarizes CYSRT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CYSRT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYSRT1 shows lower tumor expression in HNSC and KIRC and higher tumor expression in COAD, THCA, READ and LIHC. The HNSC box plot shows higher CYSRT1 RNA expression in normal versus tumor tissue (log2 FC = −2.917, t-test p < 0.001).
This table shows molecular features associated with CYSRT1 in patient tissues and cancer cell lines. In patient samples, CYSRT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYSRT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
